Email story to a friend
Printable version
GlaxoSmithKline under fire again on AIDS drugs
Date: 2 Jun 2002
GlaxoSmithKline is to be barred from marketing drugs at the outpatient sites of the AIDS Healthcare Foundation in protest at its pricing policies that the Foundation says put the company "outside the bounds of corporate responsibility".
The Foundation, one of the largest providers of specialised care for HIV patients in the US, hopes that the move will block the company's main channel to inform doctors directly about new products.Its complaint is that although the company offers reduced prices for AIDS drugs sold in the developing world it still charges twice as much as its competitors.GlaxoSmithKline has countered the charges, saying that it has reduced prices by as much as 90 percent and does not make profit on AIDS drugs sold in the developing world.
Article source: Washington Post / AP
Bookmark with:
Del.icio.us |
Digg |
reddit |
Facebook |
StumbleUpon
Comments
You must be logged in to add comments
Special Feature
Social responsibility and finance - on the precipice
In a recent article, the BBC's economics editor Robert Peston highlighted the fact that in 2012 the chances are that the economy - punch drunk as it is from the various flavours of debt crisis it has been pummelled with over the course of the year - will be hit by the collapse of a major bank and / or government.
From the same country
Ethical behaviour tied to better financial returns - 11 Jun 2008
SRI investors support UN business and human rights report - 11 Jun 2008
Business leaders lobby for carbon cuts - 20 Jun 2008
GlaxoSmithKline wins approval for bird flu vaccine - 19 May 2008
Anti-corruption enforcement strengthens but problems remain - 14 May 2008
Other stories about this company
US: GlaxoSmithKline boss promises company has changed after $3bn mis-selling fine - 26 Jul 2012
Drug companies cut vaccine prices in search of a more humane business model - 6 Jun 2011
US: Former GlaxoSmithkline executive charged as law targets individuals - 10 Nov 2010
US: GlaxoSmithKline could face $6bn risk over diabetes drug Avandia - 6 Mar 2010
UK: GlaxoSmithKline targets low cost vaccine for malaria - 21 Jan 2010
Kenya: GlaxoSmithKline agrees HIV royalty-free licensing to get medicines to the poor - 21 Jul 2009
Currently most popular stories
AccountAbility hits back at 'untenable' standards board (14 Jan 2011)
Sudan: Global Compact rejects calls to expel PetroChina (14 Jan 2009)
Arguments against corporate social responsibility - redoubled (26 Oct 2008)
Scottish Amicable fined for mis-selling (6 Mar 2003)
Four emerging trends in corporate social responsibility (8 Oct 2012)
No comments added - be the first!